Retatrutide Mechanism of Action: How a Triple Agonist Works in Research

Retatrutide (LY3437943) is a synthetic triple-receptor agonist engineered to activate the GIP, GLP-1 and glucagon receptors with a single molecule. Where semaglutide is a selective GLP-1 agonist and tirzepatide a dual GIP/GLP-1 agonist, retatrutide adds glucagon receptor signaling to the mix — the design decision that makes it a distinct reference compound in metabolic research.

The three receptors

Receptor	Endogenous ligand	Role in metabolic signaling
GIP	Glucose-dependent insulinotropic polypeptide	Incretin effect, fat-tissue signaling, insulin secretion
GLP-1	Glucagon-like peptide-1	Insulin secretion, appetite regulation, gastric emptying
Glucagon	Glucagon	Hepatic glucose output, energy expenditure, lipid oxidation

The key structural feature is a C20 fatty-diacid moiety conjugated through a linker, which extends plasma half-life via albumin binding — the same lipidization strategy used in tirzepatide.

Why the glucagon arm matters

Dual GIP/GLP-1 agonism explains appetite suppression and insulinotropic effects. The glucagon receptor component is what adds the energy expenditure dimension: glucagon signaling in liver and adipose tissue stimulates thermogenesis and lipid oxidation. In weight-loss research, this is the difference between “eat less” and “eat less and burn more.”

This makes retatrutide the reference standard for triple-agonist pharmacology — the balance of the three receptor affinities is what distinguishes it from any single- or dual-agonist compound.

Research context

Retatrutide is in late-stage clinical development (the TRIUMPH program). Published results have reported substantial weight reduction at higher doses in phase 2 data, with the effect attributed to the combination of incretin-driven appetite suppression and glucagon-driven energy expenditure. For laboratory work, it is a lyophilized research peptide supplied as a 10 mg vial — see our retatrutide research peptide page for specifications (CAS 2381089-83-2, C221H342N46O68, 99.5% purity).

Handling notes for research

• Lyophilized powder, store at -20°C
• Soluble in water and dilute acetic acid
• Reconstitute with bacteriostatic water using our reconstitution calculator — a 10 mg vial with 2 mL water gives 5 mg/mL
• Compare the triple-agonist profile with tirzepatide (dual GIP/GLP-1) and semaglutide (GLP-1 selective)